3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
6
Phase 3
3
Phase 1/2
3
Phase EARLY_PHASE1
1
Phase 4
1
Status
Active not recruiting
2
Completed
1
Sponsor Class
OTHER
4
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Conditions
Prostatic Neoplasms
3
Interventions
Carboplatin
315
Paclitaxel
303
Cisplatin
250
Docetaxel
238
pembrolizumab
230
Gemcitabine
214
Pemetrexed
158
Capecitabine
147
Rituximab
144
Bevacizumab
142
Dexamethasone
125
Fluorouracil
121
Cyclophosphamide
102
Trastuzumab
100
Doxorubicin
96
Nivolumab
93
Prednisone
92
Oxaliplatin
90
atezolizumab
75
Leucovorin
72
durvalumab
69
130-nm albumin-bound paclitaxel
68
Injections
66
Lenalidomide
63
Irinotecan
62
Bortezomib
56
Letrozole
54
Topotecan
53
Fulvestrant
53
Drug Therapy
50
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
INDUSTRY
×
Pluvicto
×
Clear all
NCT04720157
2026-05-27
PSMAddition
Novartis
Phase 3
Active not recruiting
1,140 enrolled
NCT04689828
2026-03-23
PSMAfore
Novartis
Phase 3
Active not recruiting
469 enrolled
11 charts
1 FDA
NCT03511664
2025-01-13
VISION
Endocyte
Phase 3
Completed
861 enrolled
39 charts
1 FDA